AU2015367275B2 - Improved cell therapies - Google Patents

Improved cell therapies Download PDF

Info

Publication number
AU2015367275B2
AU2015367275B2 AU2015367275A AU2015367275A AU2015367275B2 AU 2015367275 B2 AU2015367275 B2 AU 2015367275B2 AU 2015367275 A AU2015367275 A AU 2015367275A AU 2015367275 A AU2015367275 A AU 2015367275A AU 2015367275 B2 AU2015367275 B2 AU 2015367275B2
Authority
AU
Australia
Prior art keywords
subject
mscs
cells
derived
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015367275A
Other languages
English (en)
Other versions
AU2015367275A1 (en
Inventor
Elizabeth Evans
Graham Vesey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Ideas Pty Ltd
Original Assignee
Cell Ideas Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014905156A external-priority patent/AU2014905156A0/en
Application filed by Cell Ideas Pty Ltd filed Critical Cell Ideas Pty Ltd
Publication of AU2015367275A1 publication Critical patent/AU2015367275A1/en
Application granted granted Critical
Publication of AU2015367275B2 publication Critical patent/AU2015367275B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015367275A 2014-12-19 2015-12-18 Improved cell therapies Ceased AU2015367275B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014905156A AU2014905156A0 (en) 2014-12-19 Improved cell therapies
AU2014905157 2014-12-19
AU2014905157A AU2014905157A0 (en) 2014-12-19 Improved cell-based therapies
AU2014905156 2014-12-19
AU2015901929A AU2015901929A0 (en) 2015-05-26 Improved cell therapies
AU2015901929 2015-05-26
PCT/AU2015/000755 WO2016094932A1 (en) 2014-12-19 2015-12-18 Improved cell therapies

Publications (2)

Publication Number Publication Date
AU2015367275A1 AU2015367275A1 (en) 2017-06-29
AU2015367275B2 true AU2015367275B2 (en) 2021-11-18

Family

ID=56125431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015367275A Ceased AU2015367275B2 (en) 2014-12-19 2015-12-18 Improved cell therapies

Country Status (5)

Country Link
US (1) US20180221411A1 (enExample)
EP (1) EP3233097A4 (enExample)
JP (2) JP2018501241A (enExample)
AU (1) AU2015367275B2 (enExample)
WO (1) WO2016094932A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110536689A (zh) 2017-06-09 2019-12-03 国立大学法人大阪大学 扩张型心肌病治疗剂
BR112020004856A2 (pt) * 2017-09-15 2020-09-15 Cynata Therapeutics Limited método para tratar doença alérgica das vias aéreas (aad)/asma
US10702547B2 (en) * 2018-05-16 2020-07-07 Aq Skin Solutions Inc. Compositions for treatment of arthritis
CA3103043A1 (en) * 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
CA3225910A1 (en) * 2021-07-08 2023-01-12 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of osteoarthritis in animals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106367A2 (en) * 2011-01-31 2012-08-09 Royal Daniel F Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
AU2013205141A1 (en) * 2008-08-22 2013-05-16 Regeneus Ltd. Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes
US20140079672A1 (en) * 2012-02-16 2014-03-20 The Cleveland Clinic Foundation Methods for treating genitourinary disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010347212B2 (en) 2010-09-14 2016-07-14 Cell Ideas Pty Ltd Cell free preparation and uses thereof
SG10201606745XA (en) * 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013205141A1 (en) * 2008-08-22 2013-05-16 Regeneus Ltd. Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes
WO2012106367A2 (en) * 2011-01-31 2012-08-09 Royal Daniel F Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
US20140079672A1 (en) * 2012-02-16 2014-03-20 The Cleveland Clinic Foundation Methods for treating genitourinary disorder

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANDO et al., "Stem cell -conditioned medium accelerates distraction osteogenesis through multiple regenerative mechanisms", Bone, vol. 61, doi:doi:10.1016/j.bone.2013.12.029, (2014), pages 82 - 90, (2014-01-02) *
CHEN et al., Supplement: 2014 World Transplant Congress Abstracts, Jointly published by The American Society of Transplant Surgeons, The Transplantation Society and the American Society of Transplantation, (2014-06), page 416 *
DEANNE J. WHITWORTH ET AL, "Stem cell therapies for treating osteoarthritis: Prescient or premature?", VETERINARY JOURNAL, GB, (2014-12-01), vol. 202, no. 3, doi:10.1016/j.tvjl.2014.09.024, ISSN 1090-0233, pages 416 - 424 *
KORDELAS et al., "Successful treatment of therapy-refractory acute Graft-versus-Host Disease with mesenchymal stem cell -derived exosomes", Transfusion Medicine and Hemotherapy - Abstracts, (2013), vol. 40, no. 1, pages 1 - 90 *
KUPCOVA SKALNIKOVA, H. et al., "Proteomic techniques for characterisation of mesenchymal stem cell secretome", Biochimie, (2013), vol. 95, no. 12, doi:doi:10.1016/j.biochi.2013.07.015, pages 2196 - 2211 *
KYUNG JIN et al., Journal of Clinical Investigation, (2002), vol. 109, no. 9, pages 1183 - 1191 *
STERN et al., "Influence of Donor/Recipient Sex Matching on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia", 2006, vol. 82, no. 2, pages 218 - 226 *
ZHENG et al., ACR Meeting Abstracts - 2013 ACR/ARHP Annual Meeting, (2013), URL: http://acrabstracts.org/abstract/human-gingiva-derived-mesenchymalshomal-cells-inhibit-graft-versus-host-disease-through-cd39-and-ido *

Also Published As

Publication number Publication date
AU2015367275A1 (en) 2017-06-29
WO2016094932A1 (en) 2016-06-23
EP3233097A1 (en) 2017-10-25
JP2018501241A (ja) 2018-01-18
EP3233097A4 (en) 2018-08-08
US20180221411A1 (en) 2018-08-09
JP2022069524A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
Kulus et al. Mesenchymal stem/stromal cells derived from human and animal perinatal tissues—origins, characteristics, signaling pathways, and clinical trials
Prządka et al. The role of mesenchymal stem cells (MSCs) in veterinary medicine and their use in musculoskeletal disorders
US20200261510A1 (en) Therapeutics Using Adipose Cells and Cell Secretions
Arnhold et al. Adipose tissue derived mesenchymal stem cells for musculoskeletal repair in veterinary medicine
AU2015367275B2 (en) Improved cell therapies
BE1024781B1 (de) Von adipösem gewebe stammende stromale stammzellen zur verwendung bei der behandlung behandlungsresistenter komplexer perianalfisteln bei morbus crohn
US20200206272A1 (en) Treatment agent for epidermolysis bullosa
Leal Reis et al. Allogenic synovia-derived mesenchymal stem cells for treatment of equine tendinopathies and desmopathies—Proof of concept
Ossanna et al. Multilineage-differentiating stress-enduring cells (muse cells): An easily accessible, pluripotent stem cell niche with unique and powerful properties for multiple regenerative medicine applications
AU2017287529B2 (en) Prophylactic or therapeutic agent for organ fibrosis
US20210228638A1 (en) Therapeutic agent for spinal cord injury
AU2020257078B2 (en) Stem cells and secretions for treatment of inflammatory conditions
JP2018501189A (ja) 骨欠損を治療するための体性幹細胞
HK40015513A (en) Therapeutics using adipose cells and cell secretions
Brehm Evolution and actual state of veterinary regenerative medicine.
Suresh Growth factor priming of murine mesenchymal stem cells critically determines their functionality

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)